Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The aim is to investigate whether Lamivudine 100mg daily is effective in the long term
treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia